Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGT-068A
- Development stage
- Preclinical
- Lead developer
- Regor Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RGT-068A is a potent, selective, and orally bioavailable small molecule inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1). Developed by Regor Therapeutics (also referred to as Ruagen), RGT-068A is designed as a preclinical candidate for the potential treatment of autoimmune diseases and MALT1-dependent cancers, such as diffuse large B-cell lymphoma (DLBCL). The compound features a pyrazoloaminopyrimidine core, and its synthesis involves a highly efficient Heck reaction and N-directed asymmetric hydrogenation to construct its chiral ether unit.
02
Targets
BCL10 (B-cell lymphoma/leukemia 10 protein)NF-κBMALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)
Beyond the preview
Go deeper on RGT-068A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGT-068A.